



February 27, 2017

## Vericel to Present at Multiple Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the following investor conferences:

- | Cowen and Company 37th Annual Health Care Conference in Boston, MA on Wednesday, March 8, 2017 at 10:40am ET with a live webcast at [www.vcel.com/events](http://www.vcel.com/events).
- | 29th Annual ROTH Conference in Dana Point, CA on Monday, March 13, 2017 at 8:00am PT with a live webcast at [www.vcel.com/events](http://www.vcel.com/events).
- | 2017 Canaccord Genuity Musculoskeletal Conference in San Diego, CA on Tuesday, March 14, 2017 at 11:00am PT with a live webcast at [www.vcel.com/events](http://www.vcel.com/events).

### About Vericel Corporation

Vericel develops, manufactures, and markets autologous expanded cell therapies for the treatment of patients with serious diseases and conditions. The company markets three cell therapy products in the United States. Vericel is marketing MACI<sup>®</sup> (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults, which has recently been approved by the FDA. Carticel<sup>®</sup> (autologous cultured chondrocytes) is an autologous chondrocyte implant for the treatment of cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel<sup>®</sup> (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing ixmyelocel-T, an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). For more information, please visit the company's website at [www.vcel.com](http://www.vcel.com).

Epicel<sup>®</sup>, Carticel<sup>®</sup>, and MACI<sup>®</sup> are registered trademarks of Vericel Corporation. © 2017 Vericel Corporation. All rights reserved.

#### CONTACT:

Chad Rubin  
The Trout Group  
[crubin@troutgroup.com](mailto:crubin@troutgroup.com)  
(646) 378-2947  
or  
Lee Stern  
The Trout Group  
[lstern@troutgroup.com](mailto:lstern@troutgroup.com)  
(646) 378-2922